Request Demo
Fierce Pharma Asia—BeiGene's 1,400 new hires; BMS' India innovation hub; Evrenzo's China growth
Drug ApprovalLicense out/in
BeiGene's business expansion, Bristol Myers' new India facility, and changes in AstraZeneca and FibroGen's Evrenzo pact made our news this week.
BeiGene expanded its global woBristol Myers400 over the past 12 months amid fastAstraZenecaowth.FibroGen Myers Squibb has launched a new innovation hub in India, which the company expects to be its largest site outside the U.S. by 2025. AstraZeneca has decided to hold onto Evrenzo in China and Korea while returning its rights to FibroGen in the U.S. and other territories. And more.
BeiGeneene grows global workforce by 1,000-plus as Brukinsa surges, Tevimbra launches outside ChiBristol Myers SquibbAstraZenecaEvrenzoFibroGen
BeiBeiGenes grown its head count by 1,400 between early 2023 and mid-February 2024. The global expansion came as BeiGene’s product sales climbed 75% year over year to reach $2.2 billion in 2023. The growth was led by BTK inhibitor Brukinsa, which crossed the blockbuster threshold, generating $1.3 billion in sales. The company is still waiting for the FDA’s decision on its PD-1 inhibitor Tevimbra.
BriBMSl Myers Squibb has opened a new innovation hub in Hyderabad, India. The facility, built with a $100 million investment, is expected to house more than 1,500 employees. It will enhance BMS’ drug development through the use of digital technologies and artificial intelligence, CEO Chris Boerner said. The New Jersey pharma expects the facility to become its largest site outside the U.S. by 2025, Reuters reported.
Bristol Myers Squibbly drops roxadustat US rights after FDA rejection, trial failure
AstAstraZenecas parted ways wroxadustaten on the ill-fatFDAoral anemia drug roxadustat in the U.S. and certain other countries. The company kept its collaboration rights in China and South Korea, where the drug is approved as Evrenzo. Last year, Evrenzo’s sales in China rose 36% to $284 million, and FibroGen expects the figure to increase to around $300 million to $340 million this year.
AstraZenecaamp up inspections of FibroGenuring facilities in Indanemiauters)roxadustatEvrenzoEvrenzoFibroGen
TheFDAA conducted more than 200 inspections in India in 2023, and the agency is still looking to increase that number by adding more staffers to be stationed there, the FDA’s country director in India, Sarah McMullen, said, according to Reuters. The FDA official said Indian drugmakers need to invest more in automation to ensure better compliance.
Takeda has tapped India’s Biological E. Qdengap manufacture the dengue fever vaccine Qdenga. The new partner will produce multidose vials for endemic countries by 2030 at the latest. The Indian firm will produce up to 50 million doses of Qdenga per year as part of Takeda’s overall goal to make 100 million doses per year within the decade.
Biocon BJ&Jogics has joiBiocon Biologics biosimilar makers that have signed settlements with Johnson & Johnson around the blockbuster inflammatory disease drug Stelara. Biocon’s deal allows its biosimilar to enter the U.S. market in February 2025, pending an FDA approval.
Biocon Biologics up for Austedo marketing in China (Release)Johnson & Johnsoninflammatory diseaseBioconFDA
TevTevas partnered with Jiangsu Nhwa Pharmaceutical to market and distribute the Israeli pharma company’s Austedo in China. In a press release, Teva’s general manager of greater China, Theodor Wee, praised Nhwa’s “deep neuro-psychiatry expertise and capabilities.” The deal follows a trend in which foreign pharmas are increasingly relying on local companies to handle commercialization in China.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.